Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel.
COVID-19 diagnostic testing
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Sep 2021
06 Sep 2021
Historique:
received:
23
03
2021
accepted:
17
08
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
The aims of this study are to determine (i) SARS-CoV-2 antibody positive employees in Austrian trauma hospitals and rehabilitation facilities, (ii) number of active virus carriers (symptomatic and asymptomatic) during the study, (iii) antibody decline in seropositive subjects over a period of around 6 months, (iv) the usefulness of rapid antibody tests for outpatient screening. A total of 3301 employees in 11 Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA) participated in this open uncontrolled prospective cohort study. Rapid lateral flow tests, detecting a combination of IgM and IgM against SARS-CoV-2), two different types of CLIA (Diasorin, Roche), RT-PCR tests and serum neutralization tests (SNTs) were performed. The tests were conducted twice, with an interval of 42.4 ± 7.7 (Min = 30, Max = 64) days. Positive participants were re-tested with CLIA/SNT at a third time point after 188.0 ± 12.8 days. Only 27 out of 3301 participants (0.82%) had a positive antibody test at any time point during the study confirmed via neutralization test. Among positively tested participants in either test, 50.4% did not report any symptoms consistent with common manifestations of COVID-19 during the study period or within the preceding 6 weeks. In the group who tested positive during or prior to study inclusion the most common symptoms of an acute viral illness were rhinitis (21.9%), and loss of taste and olfactory sense (21.9%). Based on the neutralization test as the true condition, the rapid antibody test performed better on serum than whole blood as 84.6% instead of 65.4% could be detected correctly. Concerning both CLIA tests overall the Roche test detected 24 (sensitivity = 88.9%) and the Diasorin test 22 positive participants (sensitivity = 81.5%). In participants with a positive SNT result, a significant drop in neutralizing antibody titre from 31.8 ± 22.9 (Md = 32.0) at T1 to 26.1 ± 17.6 (Md = 21.3) at T2 to 21.4 ± 13.4 (Md = 16.0) at T3 (χ During the study period (May 11th-August 3rd) only 0.82% were tested positive for antibodies in our study cohort. The antibody concentration decreases significantly over time with 14.8% (4 out of 27) losing detectable antibodies.
Sections du résumé
BACKGROUND
BACKGROUND
The aims of this study are to determine (i) SARS-CoV-2 antibody positive employees in Austrian trauma hospitals and rehabilitation facilities, (ii) number of active virus carriers (symptomatic and asymptomatic) during the study, (iii) antibody decline in seropositive subjects over a period of around 6 months, (iv) the usefulness of rapid antibody tests for outpatient screening.
METHOD
METHODS
A total of 3301 employees in 11 Austrian trauma hospitals and rehabilitation facilities of the Austrian Social Insurance for Occupational Risks (AUVA) participated in this open uncontrolled prospective cohort study. Rapid lateral flow tests, detecting a combination of IgM and IgM against SARS-CoV-2), two different types of CLIA (Diasorin, Roche), RT-PCR tests and serum neutralization tests (SNTs) were performed. The tests were conducted twice, with an interval of 42.4 ± 7.7 (Min = 30, Max = 64) days. Positive participants were re-tested with CLIA/SNT at a third time point after 188.0 ± 12.8 days.
RESULTS
RESULTS
Only 27 out of 3301 participants (0.82%) had a positive antibody test at any time point during the study confirmed via neutralization test. Among positively tested participants in either test, 50.4% did not report any symptoms consistent with common manifestations of COVID-19 during the study period or within the preceding 6 weeks. In the group who tested positive during or prior to study inclusion the most common symptoms of an acute viral illness were rhinitis (21.9%), and loss of taste and olfactory sense (21.9%). Based on the neutralization test as the true condition, the rapid antibody test performed better on serum than whole blood as 84.6% instead of 65.4% could be detected correctly. Concerning both CLIA tests overall the Roche test detected 24 (sensitivity = 88.9%) and the Diasorin test 22 positive participants (sensitivity = 81.5%). In participants with a positive SNT result, a significant drop in neutralizing antibody titre from 31.8 ± 22.9 (Md = 32.0) at T1 to 26.1 ± 17.6 (Md = 21.3) at T2 to 21.4 ± 13.4 (Md = 16.0) at T3 (χ
CONCLUSIONS
CONCLUSIONS
During the study period (May 11th-August 3rd) only 0.82% were tested positive for antibodies in our study cohort. The antibody concentration decreases significantly over time with 14.8% (4 out of 27) losing detectable antibodies.
Identifiants
pubmed: 34488680
doi: 10.1186/s12879-021-06586-7
pii: 10.1186/s12879-021-06586-7
pmc: PMC8419821
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
915Informations de copyright
© 2021. The Author(s).
Références
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
Euro Surveill. 2020 Feb;25(5):
pubmed: 32046819
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
N Engl J Med. 2020 Oct 29;383(18):1782-1784
pubmed: 32871061
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
J Med Virol. 2020 Jul;92(7):903-908
pubmed: 32219885
Allergy. 2020 Jul;75(7):1699-1709
pubmed: 32196678
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
J Clin Med. 2020 Feb 17;9(2):
pubmed: 32079150
Acta Biomed. 2020 Sep 07;91(3):e2020003
pubmed: 32921701
Infection. 2021 Feb;49(1):95-101
pubmed: 33025521
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Radiology. 2020 Aug;296(2):E15-E25
pubmed: 32083985
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Clin Imaging. 2020 Jul;63:7-9
pubmed: 32120312
Korean J Radiol. 2020 Apr;21(4):505-508
pubmed: 32174053
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
J Microbiol Immunol Infect. 2020 Jun;53(3):485-487
pubmed: 32198005
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Lancet. 2020 Feb 22;395(10224):542-545
pubmed: 32061313
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Z Evid Fortbild Qual Gesundhwes. 2020 Aug;153:54-59
pubmed: 32419875
Radiology. 2020 Aug;296(2):E41-E45
pubmed: 32049601
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930